La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Shanghai Pharmaceuticals Holding Crescita futura

Future criteri di controllo 1/6

Shanghai Pharmaceuticals Holding prevede che gli utili e i ricavi cresceranno rispettivamente di 18.4% e 10.2% all'anno. Si prevede che l'EPS crescerà di 18.4% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 8.1% in 3 anni.

Informazioni chiave

18.4%

Tasso di crescita degli utili

18.4%

Tasso di crescita dell'EPS

Healthcare crescita degli utili	21.9%
Tasso di crescita dei ricavi	10.2%
Rendimento futuro del capitale proprio	8.1%
Copertura analitica	Good
Ultimo aggiornamento	15 Aug 2024

Aggiornamenti recenti sulla crescita futura

Earnings Miss: Shanghai Pharmaceuticals Holding Co., Ltd Missed EPS By 30% And Analysts Are Revising Their Forecasts

Apr 01

Recent updates

Shanghai Pharmaceuticals Holding (SHSE:601607) Has Some Way To Go To Become A Multi-Bagger

Aug 09

Shanghai Pharmaceuticals Holding's (SHSE:601607) Dividend Is Being Reduced To CN¥0.41

Jul 18

Shanghai Pharmaceuticals Holding (SHSE:601607) Has A Somewhat Strained Balance Sheet

Jun 25

Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Earnings Are Not Doing Enough For Some Investors

May 21

Earnings Miss: Shanghai Pharmaceuticals Holding Co., Ltd Missed EPS By 30% And Analysts Are Revising Their Forecasts

Apr 01

Returns At Shanghai Pharmaceuticals Holding (SHSE:601607) Appear To Be Weighed Down

Mar 16

We Think Shanghai Pharmaceuticals Holding (SHSE:601607) Can Stay On Top Of Its Debt

Feb 29

Previsioni di crescita degli utili e dei ricavi

SHSE:601607 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	349,747	6,580	3,442	6,711	8
12/31/2025	318,304	5,750	650	5,691	10
12/31/2024	287,499	5,071	2,099	6,742	9
3/31/2024	264,221	3,793	-769	2,381	N/A
12/31/2023	260,295	3,768	2,261	5,232	N/A
9/30/2023	254,878	4,600	4,189	7,205	N/A
6/30/2023	252,866	4,531	3,774	6,938	N/A
3/31/2023	241,310	5,884	1,813	4,610	N/A
12/31/2022	231,981	5,617	2,058	4,743	N/A
9/30/2022	229,463	5,423	-2,313	1,978	N/A
6/30/2022	222,294	5,221	-1,659	2,334	N/A
3/31/2022	221,122	4,224	-443	3,671	N/A
12/31/2021	215,824	5,093	943	5,061	N/A
9/30/2021	212,559	5,378	2,013	4,571	N/A
6/30/2021	209,982	5,621	2,863	5,310	N/A
3/31/2021	203,061	5,578	3,485	6,337	N/A
12/31/2020	191,909	4,496	3,835	6,845	N/A
9/30/2020	186,271	4,284	4,982	8,288	N/A
6/30/2020	181,156	4,237	4,118	7,705	N/A
3/31/2020	181,007	3,993	2,194	5,277	N/A
12/31/2019	186,566	4,081	3,269	6,022	N/A
9/30/2019	182,100	3,908	2,030	4,334	N/A
6/30/2019	175,781	4,134	2,167	4,077	N/A
3/31/2019	168,705	3,987	1,296	3,193	N/A
12/31/2018	159,084	3,881	1,192	3,135	N/A
9/30/2018	149,417	4,204	655	2,536	N/A
6/30/2018	140,947	3,629	520	2,470	N/A
3/31/2018	134,104	3,541	317	2,368	N/A
12/31/2017	130,847	3,521	N/A	2,649	N/A
9/30/2017	129,279	3,428	N/A	2,483	N/A
6/30/2017	126,848	3,389	N/A	2,401	N/A
3/31/2017	124,619	3,306	N/A	1,995	N/A
12/31/2016	120,765	3,196	N/A	1,947	N/A
9/30/2016	116,993	3,155	N/A	1,989	N/A
6/30/2016	114,262	3,075	N/A	1,672	N/A
3/31/2016	109,667	3,033	N/A	1,819	N/A
12/31/2015	105,517	2,877	N/A	1,349	N/A
9/30/2015	102,723	2,857	N/A	1,265	N/A
6/30/2015	99,336	2,807	N/A	1,547	N/A
3/31/2015	96,250	2,738	N/A	1,758	N/A
12/31/2014	92,399	2,591	N/A	1,336	N/A
9/30/2014	88,881	2,477	N/A	1,161	N/A
6/30/2014	83,518	2,371	N/A	906	N/A
3/31/2014	79,907	2,174	N/A	667	N/A
12/31/2013	78,223	2,214	N/A	973	N/A
9/30/2013	74,988	2,155	N/A	997	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 601607 ( 18.4% all'anno) è superiore al tasso di risparmio ( 2.9% ).

Guadagni vs Mercato: Si prevede che gli utili di 601607 ( 18.4% all'anno) cresceranno più lentamente rispetto al mercato CN ( 21.9% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 601607 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 601607 ( 10.2% all'anno) crescerà più lentamente rispetto al mercato CN ( 13.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 601607 ( 10.2% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 601607 sarà basso tra 3 anni ( 8.1 %).

Shanghai Pharmaceuticals Holding Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Earnings Miss: Shanghai Pharmaceuticals Holding Co., Ltd Missed EPS By 30% And Analysts Are Revising Their Forecasts

Price target decreased by 10% to CN¥21.59

Consensus forecasts updated

Consensus revenue estimates fall by 10%

Consensus forecasts updated

Consensus forecasts updated

Recent updates

Shanghai Pharmaceuticals Holding (SHSE:601607) Has Some Way To Go To Become A Multi-Bagger

Shanghai Pharmaceuticals Holding's (SHSE:601607) Dividend Is Being Reduced To CN¥0.41

Dividend reduced to CN¥0.41

Shanghai Pharmaceuticals Holding Co., Ltd Announces the Appointment of Zhang Wenxue as Non-Executive Director and Member of the Strategy Committee

Shanghai Pharmaceuticals Holding (SHSE:601607) Has A Somewhat Strained Balance Sheet

Shanghai Pharmaceuticals Holding Co., Ltd, Annual General Meeting, Jun 28, 2024

Shanghai Pharmaceuticals Holding Co., Ltd Announces Resignation of Chen Fashu as Non-Executive Director

Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Earnings Are Not Doing Enough For Some Investors

First quarter 2024 earnings released: EPS: CN¥0.42 (vs CN¥0.41 in 1Q 2023)

Now 22% undervalued

Earnings Miss: Shanghai Pharmaceuticals Holding Co., Ltd Missed EPS By 30% And Analysts Are Revising Their Forecasts

Shanghai Pharmaceuticals Holding Co., Ltd to Report Q1, 2024 Results on Apr 27, 2024

Full year 2023 earnings: EPS misses analyst expectations

Shanghai Pharmaceuticals Holding Co., Ltd Proposes Final Dividends for the Year Ended 31 December 2023

Shanghai Pharmaceuticals Holding Co., Ltd Announces Executive Changes

Returns At Shanghai Pharmaceuticals Holding (SHSE:601607) Appear To Be Weighed Down

We Think Shanghai Pharmaceuticals Holding (SHSE:601607) Can Stay On Top Of Its Debt

Shanghai Pharmaceuticals Holding Co., Ltd to Report Fiscal Year 2023 Results on Mar 30, 2024

Shanghai Pharmaceuticals Holding Co., Ltd Announces Change of Joint Company Secretary

Shanghai Pharmaceuticals Holding Co., Ltd Announces Resignation of Zhou Jun as the Chairman of the Company, A Non-Executive Director

Third quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.33 in 3Q 2022)

Shanghai Pharmaceuticals Holding Co., Ltd to Report Q3, 2023 Results on Oct 28, 2023

Price target decreased by 10% to CN¥21.59

Shanghai Pharmaceuticals Holding Co., Ltd Appoints SHEN Bo as President

Shanghai Pharmaceuticals Holding Co., Ltd to Report First Half, 2023 Results on Aug 30, 2023

Shanghai Pharmaceuticals Holding Co., Ltd, Annual General Meeting, Jun 29, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Consensus forecasts updated

Third quarter 2022 earnings released

Shanghai Pharmaceuticals Holding Co., Ltd to Report Q3, 2022 Results on Oct 27, 2022

Second quarter 2022 earnings released: EPS: CN¥0.66 (vs CN¥0.51 in 2Q 2021)

Shanghai Pharmaceuticals Holding Co., Ltd Announces Executive Changes

Shanghai Pharmaceuticals Holding Co., Ltd to Report Q2, 2022 Results on Aug 29, 2022

Shanghai Pharmaceuticals Holding Co., Ltd Approves Cash Dividend for the Year 2021, Payable on August 29, 2022

Shanghai Pharmaceuticals Holding Co., Ltd, Annual General Meeting, Jun 30, 2022

Investor sentiment improved over the past week

Consensus revenue estimates fall by 10%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Shanghai Pharmaceuticals Holding Co., Ltd Announces Final Dividend for the Year Ended December 31, 2021, Payable on August 30, 2022

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.51 (vs CN¥0.49 in 2Q 2020)

VP, Board Secretary & Joint Company Secretary Suet Wing Leung has left the company

Shanghai Pharmaceuticals Holding Co., Ltd (SHSE:601607) entered into an equity transfer agreement to acquire Shanghai SPH Biological Medicine Co., Ltd. from Shanghai Asia Pioneer Pharmaceuticals Co., Ltd. for CNY 750 million.

Shanghai Pharmaceuticals Holding Co., Ltd. Announces Obtaining Acceptance of Application for Clinical Trial for New Indications of Sph3127 Tablets

Shanghai Pharmaceuticals Holding Co., Ltd announced that it expects to receive CNY 14.383814049 billion in funding from Yunnan Baiyao Group Co.,Ltd, Shanghai Tandong Enterprise Consulting Services Co., Ltd.

First quarter 2021 earnings released

Shanghai Pharmaceuticals Holding Co., Ltd Proposes Cash Dividend for the Year Ended December 31, 2020, Payable Before August 30, 2021

Full year 2020 earnings released: EPS CN¥1.58 (vs CN¥1.44 in FY 2019)

Shanghai Pharmaceuticals Holding Co., Ltd to Report Fiscal Year 2020 Results on Mar 27, 2021

New 90-day high: CN¥20.47

New 90-day low: CN¥18.26

New 90-day low: CN¥18.89

New 90-day low: CN¥19.65

Third quarter 2020 earnings released: EPS CN¥0.41

Revenue and earnings beat expectations

New 90-day low: CN¥19.92

Shanghai Pharmaceuticals Holding Co., Ltd to Report Nine Months, 2020 Results on Oct 29, 2020

First half earnings released

New 90-day high - CN¥20.54

Shanghai Pharmaceuticals Holding Co., Ltd to Report First Half, 2020 Results on Aug 28, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione